Kevin D. Freeman‐Cook

Author

Also Known As

Freeman-Cook, Kevin D., K. D. FREEMAN‐COOK, K. D. Freeman-Cook, K. Freeman-Cook, Kevin D Freeman-Cook, Kevin D. Freeman-Cook, Kevin D. Freeman‐Cook, Kevin Freeman-Cook

Publications

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Colorado Boulder

About

Kevin D. Freeman‐Cook is an author at Pfizer (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	629
2	Natural Sciences	7	7	410
3	Biochemistry	7	7	410
4	Engineering	2	2	40
5	Biomolecular Engineering	1	1	24

Kevin D. Freeman‐Cook

Publications

849

Citations

H-Index

Page 1

	Year	Citations
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, Cancer Cell Tumor BiologyOncologyCdk2/4/6 InhibitorMedicineTumor Cell Cycle	2021	172
Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A Casey L. Quinlan, Stephen E. Kaiser, Ben Bolaños, Nature Chemical Biology BiosynthesisBiochemistryNatural SciencesMedicineS-adenosylmethionine Biosynthesis	2017	128
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna, Journal of Medicinal Chemistry	2021	112
Design of Selective, ATP-Competitive Inhibitors of Akt Kevin D. Freeman‐Cook, Christopher Autry, Gary Borzillo, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryPharmacotherapyLead SeriesAtp-competitive Akt Inhibitors	2010	75
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates, MedChemComm	2011	68
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2 Jeffrey W. Corbett, Kevin D. Freeman‐Cook, Richard L. Elliott, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryNatural SciencesMedicineDrug Development	2009	58
Maximizing Lipophilic Efficiency: The Use of Free-Wilson Analysis in the Design of Inhibitors of Acetyl-CoA Carboxylase Kevin D. Freeman‐Cook, Paul A. Amor, Scott J. Bader, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyChemical BiologyEnzymatic ModificationPharmaceutical Chemistry	2011	54
Identification of Tetrahydropyrido[4,3-<i>d</i>]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists David W. Piotrowski, Kentaro Futatsugi, Joseph S. Warmus, ACS Medicinal Chemistry Letters Pharmaceutical ScienceImmunologyPharmacotherapyChemical BiologyAcceptable Potency	2012	47
Potent, selective pyrimidinetrione-based inhibitors of MMP-13 Lawrence A. Reiter, Kevin D. Freeman‐Cook, Christopher S. Jones, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicinePharmacotherapyAnti-cancer AgentDrug Development	2006	47
Identification of an Inhibitor of the MurC Enzyme, Which Catalyzes an Essential Step in the Peptidoglycan Precursor Synthesis Pathway Laura E. Zawadzke, Michael Norcia, Charlene Desbonnet, Assay and Drug Development Technologies Bioorganic ChemistryAntibiotic AdjuvantGlycobiologyMolecular BiologyEscherichia Coli Murc	2008	24

Page 1